https://www.pharmacytimes.com/view/fda-awards-breakthrough-device-designations-to-signatera-molecular-residual-disease-test
FDA Awards Breakthrough Device Designations to Signatera Molecular Residual Disease Test | Pharmacy...
Oct 7, 2026 - With the breakthrough device designation granted in 2019, the Signatera MRD test now has 3 designations for use across several cancer types and indications.
molecular residual diseasefdaawardsbreakthroughdevice